NOTES FROM
THE PHARMACEUTICAL INDUSTRY

According to IQVIA free market data, in 2024, the Türkiye Pharmaceutical Market recorded a total of 2,592 million units and a market value of 314.9 billion TL (*). Compared to the same period of the previous year, the market experienced a 4.7% decline in unit sales, while achieving a 52.3% growth in TRY terms.

In the Türkiye pharmaceutical market, prescription drugs accounted for 95.2% of total unit sales and 92.4% of the market value in TRY terms.

While Türkiye imports pharmaceuticals from various therapeutic groups, the majority of imports consist of innovative and high- tech drugs, including oncology medications, blood factors, central nervous system drugs, insulin, and certain controlled- release formulations.

According to IQVIA data, in 2024, imported pharmaceutical sales declined by 5.0% in unit terms but grew by 10.3% in USD terms, reaching 3.8 billion USD. The domestic pharmaceutical market contracted by 4.6% in unit terms but expanded by 9.1% in USD terms, reaching 5.8 billion USD. The share of imported pharmaceuticals in the total market stood at 10.5% in unit terms and 39.6% in USD terms.

According to IQVIA data, in 2024, the industry as a whole contracted by 4.7% in unit terms, while it grew by 9.6% in USD terms, reaching 9.6 billion USD. The total pharmaceutical market grew by 52.3%, reaching 314.9 billion TRY.

 

(*) Due to a change in IQVIA’s calculation methodology, ‘Excess Goods’ are included in the unit value but not in the TRY value.

Source: IQVIA Free Flexview Data

In 2024, the market distribution by pharmaceutical segments in Türkiye was as follows in terms of units and TRY/USD. The “Nutrition & Metabolism” segment held the largest share in both unit and TRY/USD terms.

 

Source: IQVIA Free Flexview Data